Case Control Polysomnographic Studies of Sleep Disorders in Parkinson's Disease by Yong, Ming-Hui et al.
Case Control Polysomnographic Studies of Sleep
Disorders in Parkinson’s Disease
Ming-Hui Yong
1,3, Stephanie Fook-Chong
2, Ratnagopal Pavanni
1,3, Li-Ling Lim
1, Eng-King Tan
1,3*
1Department of Neurology, National Neuroscience Institute, Singapore, 2Department of Clinical Research, Singapore General Hospital, Singapore, 3Duke-NUS Graduate
Medical School, Singapore
Abstract
Background: The relationship between a number of primary sleep disorders and Parkinson’s disease (PD) is still debated.
There are limited case control polysomnographic studies in PD and most of these study sample sizes are small.
Methodology/Findings: We conducted one of the largest case-control studies involving overnight polysomnographic
evaluation, with prospective recruitment of unselected Parkinson’s disease patients and healthy controls from an Asian
population. The cases were recruited from the specialized movement disorder outpatient clinics in a tertiary referral center,
and controls from the same geographical locations. All subjects underwent an overnight polysomnographic study and a
multiple sleep latency test. A total of 124 subjects including 56 patients and 68 controls frequency-matched for age and sex
were included. Multivariate analysis revealed that patients had significantly shorter total sleep time than controls (p=0.01),
lower sleep efficiency (p=0.001) and increased REM latency (p=0.007). In patients, multivariate analysis showed that
reduced total sleep time was significantly associated with increased age (p=0.001) and increased levodopa dose (p=0.032).
The mean Insomnia Severity Index was higher in PD patients (9.067.1) compared to controls (3.363.9, p,0.001). The mean
Epworth Sleepiness Scale score was higher in PD patients (9.365.9 vs. 5.764.8, p,0.001). Nocturnal arousals, obstructive
sleep apnea, periodic leg movements and objective abnormal sleepiness were not increased in our patients.
Conclusions/Significance: Our case-control polysomnographic study, the first-ever performed in an Asian population,
revealed altered sleep architecture and reduced sleep in PD patients compared to controls. Reduced total sleep time was
associated with increased age and levodopa dose. However, nocturnal arousals, primary sleep disorders and abnormal
sleepiness were not increased in our PD patients suggesting that ethnic/genetic differences may be a factor in the
pathophysiology of these conditions.
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Introduction
Sleep disturbances are common in Parkinson’s disease (PD) and
adversely affect the quality of life [1,2]. Nocturnal sleep
disturbances affecting PD patients include insomnia, sleep
disordered breathing (such as obstructive sleep apnea (OSA)),
sleep-related movement disorders (restless legs syndrome (RLS),
periodic limb movements of sleep (PLMS)) and rapid eye
movement (REM) sleep behaviour disorder [1–3]. PD patients
also experience excessive daytime sleepiness (EDS) and this could
be a result of nocturnal disturbances, dopaminergic medications,
depression and hypersomnia of central origin not secondary to
nocturnal disturbances [2–5]. However, the interactions between
PD and sleep are complex because many of the sleep related
manifestations are not specific to PD.
Overnight polysomnography (PSG) is an objective method of
measuring parameters of sleep architecture and pathophysiological
events during sleep [6]. It is the gold standard for diagnosing and
evaluating the severity of sleep disorders such as sleep related
breathing disorders and PLMS [7–8]. The Multiple Sleep Latency
Test (MSLT) following overnight PSG is also the standard
barometer for objective evaluation of EDS and narcolepsy [9].
To date, only nine PSG case control studies in PD have been
reported [10–18], six of which had a small sample size (n#30)
(case or control arm) [10–15], and three of which used historical
data which prevented prospective matching [11,16–17]. There
was a selection bias for subjects referred for PSG in two of these
studies [11,16]. In addition, only two studies examined the full
spectrum of nocturnal sleep on overnight PSG and excessive
daytime sleepiness on MSLT, both of which had small sample size
in at least one arm [10,14]. Four of the overnight PSG-only studies
focused on sleep apnea in PD [12,16–18] and one focused on
REM behaviour disorder [11]. There have been no case control
PSG studies in Asia and the role of ethnic/genetic differences in
sleep related problems in PD and the link between primary sleep
disorders and PD is still unclear.
To address the limitations in the current body of literature, we
conducted one of the largest case-control studies involving
overnight PSG followed by MSLT, with prospective recruitment
of unselected PD patients and healthy controls from an Asian
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disturbances with no specific a priori hypothesis (for any sleep
disorder), both subjectively using clinical questionnaires and
objectively on PSG.
Methods
A total of 124 subjects including 56 patients diagnosed with
idiopathic PD and 68 controls frequency-matched for age (65
years) and sex participated. The PD cases were recruited from the
specialized movement disorder outpatient clinics in a tertiary
referral center. Controls were healthy volunteers without chronic
debilitating or terminal illness recruited from the same geograph-
ical locations and from advertisements in the mass media. As
diabetes mellitus, hyperlipidemia and hypertension are common
asymptomatic conditions in our general population, these were not
excluded. The participation rate was 80% in each arm. All
subjects were compensated for their transportation expenses.
Written informed consent was taken from all study participants.
The work was approved by the Singapore General Hospital and
SingHealth Ethics Review Board.
Data collection and assessment
All subjects provided demographic data and completed a
questionnaire screening for symptoms of sleep disorders (insomnia,
daytime sleepiness, obstructive sleep apnea, narcolepsy, restless
legs syndrome and other sleep related movement disorders).
Height, weight and neck circumference were measured, and the
body mass index (BMI) calculated for each subject. PD patients
provided information on their disease duration and use of
dopaminergic medications, and underwent further clinical assess-
ment using Part III (motor section) of the Unified Parkinson’s
Disease Rating Scale (mUPDRS) and modified Hoehn and Yahr
(H&Y) staging. The levodopa equivalent daily dose (LEDD) was
calculated according to the standardized formulae as: LEDD (mg/
day) = [L-dopa (mg)] + [Controlled release L-dopa (mg)60.75] +
[pramipexole (mg) 6100] + [ropinirole (mg) 620] + [piribedil
(mg)] + [bromocriptine (mg) 610] [19].
The subjects were also assessed with clinical scales to evaluate
subjective sleep disturbance: Insomnia was evaluated using the
Insomnia Severity Index (ISI): A higher ISI score reflects higher
probability of insomnia, with scores of 15 and above indicative of
clinical insomnia (of at least moderate severity). Excessive daytime
sleepiness was assessed using the Epworth Sleepiness Scale (ESS),
with a score of $10 indicating abnormal daytime sleepiness.
Subjects also completed the Beck Depression Inventory (BDI): A
higher score reflects a greater degree of depressive symptoms.
Polysomnographic study
Complete PSG was performed with a digital sleep system using
the international 10–20 electrode placement for recording C3-A2,
C4-A1, O1-A2, O2-A1 electroencephalogram (EEG), electroocu-
logram (EOG), chin electromyogram (EMG), electrocardiogram
(ECG), respiratory effort (from thoracic and abdominal respiratory
movements), oximetry, body position, airflow (nasal pressure
transducer and thermistor), snoring sound, pulse rate and limb
movement channels. Thresholds for abnormal sleep parameters
were obtained from the 2
nd edition of the International Classifica-
tion of Sleep Disorders (ICSD-2, 2005) [20]. PSG scoring followed
the Rechtschaffen and Kales scoring rules (1968) [21].
Sleep disordered breathing
Sleep disordered breathing (SDB) was defined as an apnea-
hypopnea index (AHI) of 5/hr and above. Severity of SDB was
classified as mild (AHI 5–15/hr), moderate (AHI 15.1–30/hr) or
severe (AHI .30/hr).
Periodic limb movements of sleep
Significant PLMS was defined as a periodic limb movement
index (PLMI) exceeding 15/hr.
REM sleep behavior disorder (RBD)
RBD was defined as the presence of REM sleep without atonia
(RWA) (excessive sustained or intermittent muscle activity on chin
EMG, or excessive phasic twitching on chin or limb EMG during
REM sleep) with a history of injurious, potentially injurious or
disruptive behaviour associated with sleep and/or documentation
of abnormal behaviors observed on time synchronized infrared
video recording during those periods of RWA.
Multiple Sleep Latency Test
Each subject underwent four or five 20-minute opportunities to
sleep (nap) at 2 hour intervals. For each nap, the subject was
allowed 20 minutes to fall asleep. The time taken to fall asleep was
measured, and the average of all naps taken to obtain the mean
sleep latency. After falling asleep, the subject would be awoken
after 15 minutes.
Abnormal daytime sleepiness
Abnormal daytime sleepiness was defined if a subject has mean
sleep latency of less than 8 minutes.
Statistical analysis
For univariate analysis, the Mann-Whitney U test was used to
compare continuous/ordinal variables and Fisher’s exact test to
compare frequencies between PD patients and controls. Univar-
iate correlation between variables was performed using the
Spearman rank correlation. Multivariate analysis was performed
using stepwise multiple linear regression (for continuous dependent
variables) and logistic regression (for binary dependent variables).
The threshold for significance was set at p,0.05. Analyses were
performed using the SPSS Statistics (version 17.0; Chicago: SPSS
Inc) software.
Results
Demographics
The mean age was 59.369.1 years in the control group, and
65.469.1 years in the PD patient group. 55.9% of the controls and
60.7% of PD patients were male. The mean BMI was
23.963.8 kg/m
2 in controls, and 22.863.7 kg/m
2 in PD patients.
The mean neck circumference was 36.2 63.9 cm in controls and
36.863.4 cm in PD patients. There was no significant difference
in comorbidities (hypertension, hyperlipidemia, diabetes mellitus)
between the two groups (Table 1).
PD patients had mean disease duration of 6.464.1 years. The
median modified Hoehn and Yahr (H&Y) stage was 2.5. 11
patients (19.6%) were in H&Y stages 1–1.5, 23 patients (41.1%) in
stages 2–2.5, 18 patients (32.1%) in stage 3 and 3 patients (5.4%)
in stage 4. The mean mUPDRS score was 21.5611.8. The mean
levodopa equivalent daily dose (LEDD) was 409.46265.1 mg/
day. 75.0% of the PD patients were on levodopa alone, 12.5% on
dopamine agonists alone, 8.9% on both levodopa and dopamine
agonists and 3.6% on neither levodopa nor dopamine agonists.
For the patients on dopamine agonists, the mean dopamine
agonist dose (in levodopa-equivalent units) was 72.1636.5 mg/
day. 19.6% of PD patients were on a benzodiazepine.
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significantly higher BDI scores (10.267.7 vs. 3.363.4, p,0.001
after accounting for the effect of age and sex using multiple linear
regression). 2 PD patients were on antidepressants (escitalopram
and fluoxetine).
Subjective sleep related complaints
PD patients reported more complaints of insomnia (difficulty
falling asleep, difficulty staying asleep/frequent awakenings, unre-
freshingsleep),excessivedaytimesleepiness,abnormalmovementsin
sleep and sleep talking than controls (p,0.001) (see Table 2).
Nocturnal sleep disturbances
Multivariate analysis accounting for any effect of age showed that
the mean ISI was significantly higher in PD patients (9.067.1, range 0
to 27) compared to controls (3.363.9, range 0 to 16) (p,0.001). 21.4%
of PD patients were interpreted to have clinical insomnia (ISI score
$15) compared to 1.5% of controls (p=0.006). For PD patients, we
evaluated the association between the ISI score and age, gender,
disease duration, H&Y stage, mUPDRS score, LEDD, use of
dopamine agonists and degree of depression. Increased ISI in PD
patients was significantly correlated with increased depressive
symptoms measured with the BDI (p=0.003), and multivariate
analysis confirmed this significant effect of BDI score on ISI (p=0.001).
Polysomnographic study
The overnight PSG and MSLT results are shown in Table 3. PD
patients had significantly shorter total sleep time than controls
(p=0.01), lower sleep efficiency (p=0.001) and increased REM
latency (p=0.007). Percentage of sleep spent in stage 1 was higher
in PD patients (p=0.017), while that of REM stage was reduced in
PDpatients comparedto controls(p,0.001). Thearousal index(AI)
did not differ between PD patients and controls (p=0.506).
In PD patients, multivariate analysis determined that reduced
total sleep time was significantly associated with increased age
(p=0.001) and increased LEDD (p=0.032). Reduced sleep
efficiency was associated with increased age (p=0.002) and
increased modified H&Y stage (p=0.031). BDI score was not
significantly associated with either total sleep time or sleep
efficiency despite being associated with subjective insomnia.
Percentage of sleep in REM stage correlated negatively with age
(p=0.02) but on multivariate analysis no significant factor was
found to be associated with REM stage sleep percentage. None of
the PSG parameters were found to have a significant association
with disease duration. AI did not correlate significantly with age,
disease severity or other sleep parameters.
Periodic limb movements
There was no significant difference between the PLMI between
PD patients (10.3618.1/hr) and controls (10.7621.5/hr)
(p=0.549). 26.4% of PD patients and 20.9% of controls had
significant PLM (PLMI $15) (p=0.478). In PD patients, PLMI
was not significantly associated with age, gender, disease duration,
H&Y stage, mUPDRS, LEDD, or ESS score. None of these
factors could predict for the presence of significant PLM in PD
patients.
Table 1. Demographics and Parkinson’s disease (PD) patient characteristics.
Demographics Controls (n=68) PD (n=56)
Age (years) 59.369.1 [41, 85] 65.469.1 [36, 83]
Gender
Male 55.9% 60.7%
Female 44.1% 39.3%
BMI (kg/m
2) 23.963.8 [17.9, 35.9] 22.863.7 [15.6, 32.1]
Neck circumference (cm) 36.263.9 [21.5, 46.0] 36.863.4 [30.0, 43.0]
Comorbidities
Hypertension 26.5% 32.1%
Hyperlipidemia 27.9% 30.4%
Diabetes mellitus 7.4% 12.5%
Use of a benzodiazepine 0.0% 19.6%
Characteristics of PD patients
Disease duration (years) 6.464.1 [1,19]
Modified Hoehn & Yahr stage 2.5 [1,4]
mUPDRS 21.5611.8 [5, 62]
Medications
Levodopa equivalent daily dose (mg/day) 409.46265.1 [0, 1100]
Levodopa 83.9%
DA 21.4%
Levodopa only 75.0%
DA only 12.5%
Levodopa and DA 8.9%
Neither levodopa nor DA 3.6%
BMI: body mass index, DA: dopamine agonist.
All continuous values were expressed as mean 6 SD [min, max] except for Hoehn & Yahr stage of PD patients, which was expressed as median [min, max].
doi:10.1371/journal.pone.0022511.t001
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There was no significant difference in the AHI between PD
patients (12.5615.6/hr) and controls (12.2613.1/hr) (p=0.999).
The mean central apnea index (CAI) was extremely low and
clinically insignificant in both groups (0.6864.7/hr in PD patients,
and 0.2260.61/hr in controls). 49.1% of PD patients had OSA
compared to 65.7% of controls. 15.1% of the PD patients had mild
OSA, 18.9% had moderate OSA, and 15.1% had severe OSA. In
controls 37.3% had mild OSA, 19.4% had moderate OSA and
9.0% had severe OSA. 96.2% and 38.4% of PD patients with
OSA reported snoring and feeling unrefreshed on waking from
sleep respectively, and 40% had abnormal ESS scores. On MSLT
26.9% of PD patients with OSA had abnormal daytime sleepiness.
Snoring was the only significant predictor of OSA in the
multivariate analysis (p=0.001).
Relation of subjective poor nocturnal sleep to overnight
PSG parameters in PD patients
In PD patients, increased ISI was significantly correlated with
reduced sleep efficiency (p=0.019). It also correlated with reduced
total sleep time (p=0.07). There was no significant correlation between
the ISI and the sleep onset latency, stages of sleep, AI, AHI or PLMI.
Table 2. Percentage of controls and PD patients with individual sleep complaints.
Sleep complaint
Controls
(n=68)
PD patients
(n=56)
p-value
(Fisher’s exact test)
p-value (Multivariate
analysis
a)
Difficulty falling asleep 4.4% 41.1% ,0.001 ,0.001
Difficulty staying asleep 5.9% 46.4% ,0.001 ,0.001
Unrefreshing sleep 2.9% 39.3% ,0.001 ,0.001
Snoring 50.0% 67.9% 0.067 0.053
Excessive daytime sleepiness 2.9% 66.1% ,0.001 ,0.001
Abnormal movements in sleep 7.4% 46.4% ,0.001 ,0.001
Acting out dreams 0.0% 30.4% ,0.001 -
Sleep talking 5.9% 51.8% ,0.001 ,0.001
aForward (Wald) stepwise logistic regression taking into account effects of age and sex.
doi:10.1371/journal.pone.0022511.t002
Table 3. PSG and MSLT sleep parameters and sleep disorders present in study subjects.
Sleep parameter Controls PD
p-value
(Univariate analysis
a)
p-value
(Multivariate analysis
b)
Total sleep time (min) 340.2684.6 277.16104.4 ,0.001 0.010
Sleep efficiency (%) 76.6618.3 59.4622.0 ,0.001 0.001
Sleep onset latency (min) 19.2629.1 40.3668.6 0.082 0.133
REM latency (min) 128.2679.8 177.06104.1 0.013 0.007
% stage 1 sleep 13.068.8 21.3616.7 0.010 0.017
% stage 2 sleep 48.0611.2 46.0616.4 0.665 0.849
% deep sleep 21.6610.7 23.1617.3 0.881 0.466
% REM sleep 17.166.9 8.567.4 ,0.001 ,0.001
Arousal index (/hr) 13.468.5 12.968.5 0.898 0.506
PLMI (/hr) 10.7621.5 10.3618.1 0.595 0.549
AHI (/hr) 12.2613.1 12.5615.6 0.302 0.999
MSL (min) 9.564.2 12.565.6 0.002 0.010
Presence of sleep disorders
Significant PLMS 20.9% 26.4% 0.519 0.478
OSA 65.7% 49.1% 0.062 0.043
RBD 0% 0% - -
Abnormal daytime sleepiness 39.4% 23.6% 0.080 0.208
AHI: Apnea-hypopnea index, PLMI: periodic limb movements index, MSL: mean sleep latency, PLMS: periodic limb movements of sleep, OSA: obstructive sleep apnea,
RBD: REM sleep behaviour disorder, RLS: restless legs syndrome.
Continuous variables are expressed as mean 6 SD.
aMann-Whitney U test was used to compare continuous variables, and Exact Fisher’s test to compare frequencies
bStepwise multiple linear regression was used for continuous variables and forward (Wald) stepwise logistic regression for binary outcomes (presence of each sleep
disorder). Multivariate analysis took into account any effects of age and sex (and in the case of OSA and AHI, any effect of BMI and neck circumference).
N.B. Overnight PSG reports for 3 PD patients and 1 control, and MSLT reports for 1 PD patient and 2 controls were missing. They were not included in the relevant
analyses.
doi:10.1371/journal.pone.0022511.t003
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53 PD patients and 60 controls underwent a clinical assessment
by a sleep neurologist for sleep disorders. Of these, 22.6% of the
PD patients but 0% of controls provided a clinical history
suggesting possible REM behaviour disorder. However, the
diagnosis of RBD in these subjects could not be confirmed: On
overnight PSG there was no evidence of RBD for all of our
subjects.
Restless legs syndrome
5.7% (n=3) of PD patients and 1.7% (n=1) of controls who
underwent the clinical assessment were diagnosed to have RLS
(p=0.252). Of these 4 subjects, 1 PD patient with RLS also
experienced significant PLMS on overnight PSG (PLMI $15).
Daytime sleepiness
The mean ESS score was significantly higher in PD patients
(9.365.9, range 0 to 23) than in controls (5.764.8, range 0 to 21)
(p,0.001), with 41.1% of PD patients having an abnormally high
ESS score ($10) compared to 19.1% of controls (p=0.01). In
patients, ESS score was significantly correlated with H&Y stage
(p=0.033), mUPDRS score (p=0.025), LEDD (p=0.041), BDI
score (p=0.002) and ISI score (p=0.021). After multivariate
analysis, BDI score was found to be the only factor significantly
associated with ESS score (p=0.01).
Multiple Sleep Latency Test
The mean sleep latency (MSL) was lower in controls
(9.564.2 min) than PD patients (12.565.6 min) (p=0.010).
Abnormal daytime sleepiness (MSL ,8 min) was found in
39.4% of controls and 23.6% of PD patients (p=0.208). 16.7%
of controls and 12.7% of PD patients had severe excessive daytime
sleepiness (MSL ,5 min) (p=0.544). No sleep onset REM periods
were observed in any of the naps of PD patients. Of the 13 PD
patients with abnormal daytime sleepiness, 9 had a primary sleep
disorder on overnight PSG: 6 patients had OSA, 2 patients had
abnormal PLM and 1 patient had both OSA and abnormal PLM.
For PD patients, mean sleep latency was not significantly
associated with age, gender, disease duration, H&Y stage,
mUPDRS, LEDD or dopamine use.
Gender differences in sleep parameters on PSG and MSLT
We compared the sleep stages between men and women
within each group. In each group, there was no significant
difference in age between men and women. In the control
group, gender differences in sleep architecture were in line with
that reported in the literature [22]: percentage of sleep time
spent in stage 1 was increased in men compared to women
(15.3610.1% vs. 10.265.8%, p=0.013) and deep sleep
percentage was reduced in men (18.6610.2% for men vs.
25.3610.4% for women, p=0.009). These trends did not seem
to be disrupted in our PD group: Deep sleep percentage was
reduced in men compared to women (20.6619.7 vs. 27.0612.5)
(p=0.039). Percentage of sleep in stage 1 was higher in men
than women (25.7619.1 vs. 14.669.0), but this only almost
reached significance (p=0.069).
Effect of medications on sleep in PD patients
Comparisons between PD patients on levodopa treatment alone
and PD patients on dopamine agonist treatment alone showed a
significant difference only in stage 2 sleep – this was increased in
patients on agonist only (43.2615.5% vs. 61.3615.3%, p=0.009),
but not other PSG parameters.
Discussion
We conducted a comprehensive case control PSG study to
evaluate a wide spectrum of sleep symptoms in PD. Our study
demonstrated that PD patients experience poorer nocturnal sleep
quality, as manifested by a greater frequency of sleep complaints and
a higher degree of insomnia measured on the ISI. More severe
insomnia in PD patients was supported by overnight PSG findings of
lower total sleep time and sleep efficiency in PD patients than
controls, but there was no increase in arousals or primary sleep
disorders on PSG (OSA, PLMS and RBD) to suggest these as
dominant causes of reduced nocturnal sleep in PD patients, and
parameters measuring these disorders (AI, AHI, PLMI) also did not
correlate significantly with the ISI, total sleep time or sleep efficiency.
Altered sleep architecture compared to controls (increased REM
latency, reduced percentage of sleep time spent in REM stage and
increased stage 1 sleep compared to controls) was found in PD
patients but no significant effect of this on the ISI was found.
Our data suggest that certain clinical factors were associated with
nocturnal sleep disturbances. PD patients with more depressive
symptoms had greater subjective insomnia, although there was no
significant association between BDI and reduced total sleep time or
sleep efficiency. Reduced total sleep time was associated with
increased age and LEDD while reduced sleep efficiency was
associated with increased age and H&Y stage. The poorer sleep
efficiency seen with increased H&Y stage may be due to increased
motor disability and, in part, higher LEDD in patients with more
severe PD, or reflect progressive intrinsic pathology of PD affecting
sleep centres in the brain. A negative correlation between total sleep
time and levodopa dose has also beenpreviously reported by Happe
et al. (2005) [13]. Diederich et al. (2009) did not find a correlation
between LEDD and total sleep time or percentage of sleep spent in
deep sleep; however they found an increased proportion of patients
with relatively high deep sleep percentage in the patient group with
an intermediate LEDD range [23]. The effects of dopaminergic
drugs on sleep are known to be dose dependent, with lower doses
promoting deep and REM sleep and reducing wakefulness, and
higher doses having the opposite effect, possibly due to differential
activation of D1 and D2 receptors [24]. Our results imply that
dosage of dopaminergic treatment to improve total sleep time in PD
patients suffering from nocturnal motor symptoms needs to be
adjusted to balance the benefit from relief of these symptoms and
the alerting doperminergic effect at higher doses. Controlled release
levodopa or dopamine agonists are commonly suggested to achieve
improved sleep in PD patients by relieving nocturnal motor
symptoms such as akinesia[13,24–27], though it is not well
established if they improve total sleep time: Van den Kerchove
et al. (1993) found a reduction in total time awake with sustained-
release levodopa [24,26] and Stocchi et al. (1998) reported an
increase in sleep time with chronic-release levodopa/carbidopa that
only almost reached significance [28], while Wailke et al. (2011) did
not find an increase in total sleep time with controlled-release
levodopa/carbidopa [15]. It is not certain if individualized
optimization of levodopa dosage for each patient in such studies
would help to improve total sleep time.
Optimizing subjective sleep quality also involves management of
depressive symptoms in PD patients, and sedative antidepressants
taken in the evening may help improve nocturnal sleep in PD
patients with insomnia [27].
PD patients also experienced more severe daytime sleepiness
subjectively as measured by the ESS than controls. Interestingly,
this was not supported objectively by our MSLT results; there was
no significant difference between the proportion of PD patients
with abnormal sleepiness and that of controls. Again, increased
Polysomnographic Studies in Parkinson’s Disease
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of daytime sleepiness on the ESS scale, and treatment of these
symptoms may be helpful. Although subjective sleepiness mea-
sured by ESS was positively correlated with subjective insomnia
(ISI), total sleep time, sleep efficiency and other measured
parameters on overnight PSG were not significantly associated
with increased ESS score. Although levodopa and dopamine
agonists are regarded as contributors to daytime sleepiness, there
was no correlation between LEDD and MSL. There were no
significant differences in mean ESS score or MSL detected
between PD patients on dopamine agonist treatment and those on
levodopa treatment only, although only 21.4% of our PD patients
were taking dopamine agonists. Rye et al. (2000) also found no
correlation between MSL and levodopa daily dose [10]. Arnulf
et al. (2002) found only a weak correlation between MSL and
levodopa daily dose, but no correlation with dopamine agonist
daily dose or LEDD in PD patients with daytime sleepiness [29].
T h ep r e v a l e n c eo fO S Aa n dA H Iw a sn o ti n c r e a s e di nt h eP D
group. PD patients with OSA had reduced deep and REM sleep
compared to PD patients without OSA, however the presence of OSA
(and AHI) did not affect the total sleep time, sleep efficiency, subjective
insomnia, or daytime sleepiness experienced by PD patients. Other
PSG studies by Cochen de Cock et al. (2010), Trotti et al. (2010) and
Diederich et al. (2005) found no increased prevalence and severity of,
or increased impact on sleep by sleep apnea in PD patients [16–18].
On the other hand, Shpirer et al. (2006) and Maria et al. (2003) found
increased prevalence and severity of sleep apnea [12,14].
None of the PD patients in our study were observed to have
RBD on overnight PSG, while prevalences of 16–50% have been
reported in previous PSG studies [11,30,31]. RBD may not
manifest daily and it is still possible that some of the patients in our
study did have RBD, evidence of which we were not able to
capture with only one night of PSG.
Other hypothesized relationships between PD and altered sleep
architecture have not been consistently proven in PSG studies either.
Diederich et al. (2005) previously reported that changes in nocturnal
sleep architecture are progressive with disease duration, with findings
that total sleep time, REM sleep time and sleep efficiency decreased
as disease duration increased [32]. However, in our study we did not
find a significant association between disease duration and the sleep
parameters on overnight PSG or MSLT. Happe S et al. (2005) also
did not find any correlation between overnight PSG parameters and
disease duration [13]. In previous studies on excessive daytime
sleepiness, Rye et al. (2000), Arnulf I et al. (2002) and Poryazova et al.
(2010) did not find an association between reduced MSL and disease
duration [10,29,33]. In addition, we and Shpirer et al. (2006) did not
find a significant decrease in percentage of time spent in deep sleep in
PD patients compared to controls as was reported by Wailke et al.
(2011) [14,15]. Diederich et al. (2005) found increased, rather than
decreased, deep sleep time in PD patients compared to age-, sex- and
AHI-matched controls [16]. Methodological differences (retrospec-
tive vs. prospective recruitment and sources of controls) as well as
differences in patient characteristics and medications may partly
explain variances in published studies.
Geneticinfluencesoncircadianrhythmandvarioussleepdisorders
are being increasingly recognized [34], and may be an additional
factor accounting for the differences between our prevalence of
primary sleep disorders and that found in the Westernliterature.This
isillustratedbythediscoveryofgeneticvariantsthatincreasedtherisk
o fR L Sw i t h i na nI c e l a n d i cp o p u l a t i o n[ 3 5 , 3 6 ] ,a n dt h em u c hl o w e r
prevalence of RLS in Asian populations compared to Caucasian
populations [37]. Genes influencing craniofacial morphology,
obesity, pharyngeal muscle control of the upper airway and ventilator
control,togetherwithenvironmentalinfluencesmayaffectriskforthe
development of OSA [34,38].
Our study has limitations. We evaluated one night of PSG and
one day of MSLT, as such our results may have been influenced by
a first night effect and any day-to-day variationof sleep disturbances
in our subjects. However, this is the standard practice for the
evaluation of sleep disorders, and applied to both PD patients and
controls, as such a fair comparison between the two groups could
stillbemade.Also,differencesinstudydesignandPDpatientprofile
(with regards to disease duration, disease severity and medication
dosages) compared to other published studies prevent us from
attributing differences in our findings entirely to genetic differences
in the Asian population. Lastly, as we recruited PD patients with
different stages of disease, our study does not distinguish between
sleep dysfunction that affects all PD patients as a whole and that
which affects only PD patients at a particular stage of disease.
In conclusion, our case control PSG study, the first-ever
performed in an Asian population, showed altered sleep
architecture and reduced sleep on overnight PSG in PD patients
compared to controls. Reduced total sleep time was associated
with increased age and levodopa dose. However, unlike some
smaller studies in Caucasians, nocturnal arousals, primary sleep
disorders and abnormal daytime sleepiness were not increased in
our PD patients, suggesting that ethnic/genetic differences may be
a factor in the pathophysiology of these conditions. Treating
depressive symptoms and judicious adjustment of dopaminergic
medications may be useful in managing subjective sleep-related
complaints in PD patients.
Acknowledgments
The authors thank SW Koh and SQ Su, two of our previous employees
who helped to arrange the PSG studies for the study subjects and helped
conduct the interviews. They also thank the staff from the Singapore
General Hospital Sleep Disorders Unit.
Author Contributions
Conceived and designed the experiments: M-HY L-LL E-KT. Performed
the experiments: M-HY L-LL E-KT RP. Analyzed the data: SF-C RP.
Contributed reagents/materials/analysis tools: SF-C. Wrote the paper: E-
KT M-HY L-LL RP SF-C.
References
1. Chaudhuri KR, Healy DG, Schapira AH (2006) Non-motor symptoms of
Parkinson’s disease: diagnosis and management. Lancet Neurol 5: 235–
245.
2. Menza M, Dobkin RD, Marin H, Bienfait K (2010) Sleep disturbances in
Parkinson’s disease. Mov Disord 25: S117–S122.
3. Zoccolella S, Savarese M, Lamberti P, Manni R, Pacchetti C, et al. (2011) Sleep
disorders and the natural history of Parkinson’s disease: the contribution of
epidemiological studies. Sleep Med Rev 15: 41–50.
4. Mitra T, Chaudhuri KR (2009) Sleep dysfunction and role of dysautonomia in
Parkinson’s disease. Parkinsonism Relat Disord 15: S93–S95.
5. Arnulf I, Leu-Semenescu S (2009) Sleepiness in Parkinson’s disease. Parkinson-
ism Relat Disord 15: S101–S104.
6. Littner M, Hirshkowitz M, Kramer M, Kapen S, Anderson WM, et al. (2003)
Practice parameters for using polysomnography to evaluate insomnia: an
update. Sleep 26: 754–760.
7. Kushida CA, Littner MR, Morgenthaler T, Alessi CA, Bailey D, et al. (2005)
Practice parameters for the indications for polysomnography and related
procedures: an update for 2005. Sleep 28: 499–521.
8. Epstein LJ, Kristo D, Strollo PJ, Jr., Friedman N, Malhotra A, et al. (2009)
Clinical guideline for the evaluation, management and long-term care of
obstructive sleep apnea in adults. J Clin Sleep Med 5: 263–276.
9. Littner MR, Kushida C, Wise M, Davila DG, Morgenthaler T, et al. (2005)
Practice parameters for clinical use of the multiple sleep latency test and the
maintenance of wakefulness test. Sleep 28: 113–121.
Polysomnographic Studies in Parkinson’s Disease
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e2251110. Rye DB, Bliwise DL, Dihenia B, Gurecki P (2000) FAST TRACK: daytime
sleepiness in Parkinson’s disease. J Sleep Res 9: 63–69.
11. Eisensehr I, v Lindeiner H, Ja ¨ger M, Noachtar S (2001) REM sleep behaviour
disorder in sleep-disordered patients with versus without Parkinson’s disease: is
there a need for polysomnography? J Neurol Sci 186: 7–11.
12. Maria B, Sophia S, Michalis M, Charalampos L, Andreas P, et al. (2003) Sleep
breathing disorders in patients with idiopathic Parkinson’s disease. Respir Med
97: 1151–1157.
13. Happe S, Klo ¨sch G, Lorenzo J, Kunz D, Penzel T, et al. (2005) Perception of
sleep: subjective versus objective sleep parameters in patients with Parkinson’s
disease in comparison with healthy elderly controls. Sleep perception in
Parkinson’s disease and controls. J Neurol 252: 936–943.
14. Shpirer I, Miniovitz A, Klein C, Goldstein R, Prokhorov T, et al. (2006)
Excessive daytime sleepiness in patients with Parkinson’s disease: a polysomno-
graphy study. Mov Disord 21: 1432–1438.
15. Wailke S, Herzog J, Witt K, Deuschl G, Volkmann J (2011) Effect of controlled-
release levodopa on the microstructure of sleep in Parkinson’s disease.
Eur J Neurol 18: 590–596.
16. Diederich NJ, Vaillant M, Leischen M, Mancuso G, Golinval S, et al. (2005)
Sleep apnea syndrome in Parkinson’s disease. A case-control study in 49
patients. Mov Disord 20: 1413–1418.
17. Trotti LM, Bliwise DL (2010) No increased risk of obstructive sleep apnea in
Parkinson’s disease. Mov Disord 25: 2246–2249.
18. Cochen De Cock V, Abouda M, Leu S, Oudiette D, Roze E, et al. (2010) Is
obstructive sleep apnea a problem in Parkinson’s disease? Sleep Med 11:
247–252.
19. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, et al. (2010) Systematic
review of levodopa dose equivalency reporting in Parkinson’s disease. Mov
Disord 25: 2649–2653.
20. American Academy of Sleep Medicine (2005) International classification of sleep
disorders, 2
nd ed.:Diagnostic and coding manual. Westchester, Illinois: American
Academy of Sleep Medicine.
21. Rechtschaffen A, Kales A, eds (1968) A manual of standardized terminology,
techniques and scoring system for sleep stages of human subjects. Los Angeles:
Brain Information Service/Brain Research Institute, UCLA.
22. Armitage R, Baker FC, Parry BL (2005) The Menstrual Cycle and Circadian
Rhythms. In: Kryger MH, Roth T, Dement WC, eds. Principles and practice of
sleep medicine. Philadelphia: Elsevier Saunders. pp 1266–1277.
23. Diederich NJ, Paolini V, Vaillant M (2009) Slow wave sleep and dopaminergic
treatment in Parkinson’s disease: a polysomnographic study. Acta Neurol Scand
120: 308–313.
24. Chaudhuri KR, Schapira AH (2009) Non-motor symptoms of Parkinson’s
disease: dopaminergic pathophysiology and treatment. Lancet Neurol 8:
464–474.
25. Barone P, Amboni M, Vitale C, Bonavita V (2004) Treatment of nocturnal
disturbances and excessive daytime sleepiness in Parkinson’s disease. Neurology
63: S35–S38.
26. Dhawan V, Healy DG, Pal S, Chaudhuri KR (2006) Sleep-related problems of
Parkinson’s disease. Age Ageing 35: 220–228.
27. Korczyn AD (2006) Management of sleep problems in Parkinson’s disease.
J Neurol Sci 248: 163–166.
28. Stocchi F, Barbato L, Nordera G, Berardelli A, Ruggieri S (1998) Sleep disorders
in Parkinson’s disease. J Neurol 245: S15–S18.
29. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, et al. (2002)
Parkinson’s disease and sleepiness: an integral part of PD. Neurology 58:
1019–1024.
30. Wetter TC, Trenkwalder C, Gershanik O, Ho ¨gl B (2001) Polysomnographic
measures in Parkinson’s disease: a comparison between patients with and
without REM sleep disturbances. Wien Klin Wochenschr 113: 249–253.
31. Comella CL, Tanner CM, Ristanovic RK (1993) Polysomnographic sleep
measures in Parkinson’s disease patients with treatment-induced hallucinations.
Ann Neurol 34: 710–714.
32. Diederich NJ, Vaillant M, Mancuso G, Lyen P, Tiete J (2005) Progressive sleep
‘destructuring’ in Parkinson’s disease. A polysomnographic study in 46 patients.
Sleep Med 6: 313–318.
33. Poryazova R, Benninger D, Waldvogel D, Bassetti CL (2010) Excessive daytime
sleepiness in Parkinson’s disease: characteristics and determinants. Eur Neurol
63: 129–135.
34. Taheri S, Mingot E (2002) The genetics of sleep disorders. Lancet Neurol 1:
242–250.
35. Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, et al. (2007)
Genome-wide association study of restless legs syndrome identifies common
variants in three genomic regions. Nat Genet 39: 1000–1006.
36. Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, et al. (2007) A genetic
risk factor for periodic limb movements in sleep. N Engl J Med 357: 639–647.
37. Tan EK, Seah A, See SJ, Lim E, Wong MC, et al. (2001) Restless legs syndrome
in an Asian population: A study in Singapore. Mov Disord 16: 577–579.
38. Kent BD, Ryan S, McNicholas WT (2010) The genetics of obstructive sleep
apnoea. Curr Opin Pulm Med 16: 536–542.
Polysomnographic Studies in Parkinson’s Disease
PLoS ONE | www.plosone.org 7 July 2011 | Volume 6 | Issue 7 | e22511